贝林妥欧单抗联合化疗个体化治疗婴儿白血病的病例报道<sup>★</sup>

doi:10.3969/j.issn.2095-1264.2024.05.20

首页 > 过刊浏览>2024年第5期 >645-648. DOI:10.3969/j.issn.2095-1264.2024.05.20

贝林妥欧单抗联合化疗个体化治疗婴儿白血病的病例报道★
DOI:
                        10.3969/j.issn.2095-1264.2024.05.20
                    
作者:
                        
                        
                    
作者单位:1.首都医科大学附属北京儿童医院保定医院，药剂科，河北 保定，071000;2.首都医科大学附属北京儿童医院保定医院，血液肿瘤科/河北省儿童感染性疾病发病机制及精准诊治研究重点实验室/保定市儿童血液病与肿瘤精准诊治研究实验室，河北 保定，071000
作者简介:史校东，女，硕士，主管药师，研究方向为肿瘤临床药学。
通讯作者:
中图分类号:R733.7;R725.5
基金项目:★保定市科技计划项目（2441ZF139）。

A case of individualized treatment of blinatumomab combined with chemotherapy for infant leukemia^★

Author:

Affiliation:

1.Department of Pharmacy, Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding, 071000, Hebei, China;2.Hematologic Oncology Department/Hebei Key Laboratory of Infectious Diseases Pathogenesis and Precise Diagnosis and Treatment/Baoding Key Laboratory of Pediatric Hematology Oncology, Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding, 071000, Hebei, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

目的分析1例婴儿急性B淋巴细胞白血病（B-ALL）的病例，探讨贝林妥欧单抗治疗婴儿白血病的安全性及有效性。方法回顾性分析1例婴儿B-ALL的个体化治疗方案，并结合文献复习，监测贝林妥欧单抗的安全性和有效性。结果婴儿诱导化疗后微小残留病灶（MRD）阳性且不耐受强化疗，调整为贝林妥欧单抗联合低剂量化疗、去甲基化药物个体化治疗，MRD转阴且持续阴性，未发生严重不良反应。结论贝林妥欧单抗联合低剂量化疗、去甲基化药物个体化治疗婴儿白血病疗效显著，且安全性良好。

Abstract:

Objective To analyze a case of infant B-acute lymphoblastic leukemia (B-ALL), and to explore the safety and efficacy of blinatumomab in the treatment of infant B-ALL.Methods The individualized treatment of an infant with B-ALL was retrospectively analyzed, and the safety and efficacy of blinatumomab were monitored in combination with literature review.Results After induction chemotherapy, the infant had a positive minimum residual disease (MRD) and was intolerant to intensive chemotherapy. Then the infant was given individualized treatment adjusted as blinatumomab combined with low-dose chemotherapy and hypomethylating drugs. His MRD become negative and continued to be negative. No serious adverse reactions occurred.Conclusion Blinatumomab combined with low-dose chemotherapy and hypomethylating drugs has significant efficacy and good safety in the individualized treatment of infant leukemia.